Sökning: WFRF:(Horvath György) >
Intraperitoneal alp...
-
Andersson, Håkan,1944Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
(författare)
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
- Artikel/kapitelEngelska2009
Förlag, utgivningsår, omfång ...
-
2009-06-12
-
Society of Nuclear Medicine,2009
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/108207
-
https://gup.ub.gu.se/publication/108207URI
-
https://doi.org/10.2967/jnumed.109.062604DOI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
The alpha-emitter (211)At labeled to a monoclonal antibody has proven safe and effective in treating microscopic ovarian cancer in the abdominal cavity of mice. Women in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma were enrolled in a phase I study. The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity. METHODS: Nine patients underwent laparoscopy 2-5 d before the therapy; a peritoneal catheter was inserted, and the abdominal cavity was inspected to exclude the presence of macroscopic tumor growth or major adhesions. (211)At was labeled to MX35 F(ab')(2) using the reagent N-succinimidyl-3-(trimethylstannyl)-benzoate. Patients were infused with (211)At-MX35 F(ab')(2) (22.4-101 MBq/L) in dialysis solution via the peritoneal catheter. gamma-Camera scans were acquired on 3-5 occasions after infusion, and a SPECT scan was acquired at 6 h. Samples of blood, urine, and peritoneal fluid were collected at 1-48 h. Hematology and renal and thyroid function were followed for a median of 23 mo. RESULTS: Pharmacokinetics and dosimetric results were related to the initial activity concentration (IC) of the infused solution. The decay-corrected activity concentration decreased with time in the peritoneal fluid to 50% IC at 24 h, increased in serum to 6% IC at 45 h, and increased in the thyroid to 127% +/- 63% IC at 20 h without blocking and less than 20% IC with blocking. No other organ uptakes could be detected. The cumulative urinary excretion was 40 kBq/(MBq/L) at 24 h. The estimated absorbed dose to the peritoneum was 15.6 +/- 1.0 mGy/(MBq/L), to red bone marrow it was 0.14 +/- 0.04 mGy/(MBq/L), to the urinary bladder wall it was 0.77 +/- 0.19 mGy/(MBq/L), to the unblocked thyroid it was 24.7 +/- 11.1 mGy/(MBq/L), and to the blocked thyroid it was 1.4 +/- 1.6 mGy/(MBq/L) (mean +/- SD). No adverse effects were observed either subjectively or in laboratory parameters. CONCLUSION: This study indicates that by intraperitoneal administration of (211)At-MX35 F(ab')(2) it is possible to achieve therapeutic absorbed doses in microscopic tumor clusters without significant toxicity.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Cederkrantz, ElinGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xhaeli
(författare)
-
Bäck, Tom,1964Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xbackt
(författare)
-
Divgi, ChaitanyaGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
(författare)
-
Elgqvist, Jörgen,1963Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xelgjo
(författare)
-
Himmelman, JakobGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
(författare)
-
Horvath, György,1942Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xhorgy
(författare)
-
Jacobsson, Lars,1947Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xjacla
(författare)
-
Jensen, Holger
(författare)
-
Lindegren, Sture,1960Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xlistu
(författare)
-
Palm, Stig,1964Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xpalst
(författare)
-
Hultborn, Ragnar,1946Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xhulra
(författare)
-
Göteborgs universitetInstitutionen för kliniska vetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of nuclear medicine : official publication, Society of Nuclear Medicine: Society of Nuclear Medicine50:7, s. 1153-600161-5505
-
Ingår i:Journal of Nuclear Medicine: Society of Nuclear Medicine50:7, s. 1153-602159-662X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Andersson, Håkan ...
-
Cederkrantz, Eli ...
-
Bäck, Tom, 1964
-
Divgi, Chaitanya
-
Elgqvist, Jörgen ...
-
Himmelman, Jakob
-
visa fler...
-
Horvath, György, ...
-
Jacobsson, Lars, ...
-
Jensen, Holger
-
Lindegren, Sture ...
-
Palm, Stig, 1964
-
Hultborn, Ragnar ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Journal of nucle ...
-
Journal of Nucle ...
- Av lärosätet
-
Göteborgs universitet